Manufacturer
RANBAXY LABORATORIES LIMITED
Contents
Fenofibrate
Indication
Severe hypertriglyceridaemia and Mixed hyperlipidaemia
Instruction
Should be taken with food.
Drug interaction
May increase risk of ciclosporin-induced nephrotoxicity. May increase risk of bleeding with oral anticoagulants (e.g. warfarin). Increased risk of myopathy and rhabdomyolysis with colchicine, HMG-CoA reductase inhibitors, and other fibrates. May enhance adverse effects of ezetimibe. May decrease absorption with bile acid sequestrants (except colesevelam).
Malaysia
